Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma

Ke Lin, Ba D. Nguyen, David S Ettinger, Bennett B. Chin

Research output: Contribution to journalArticle

Abstract

Purpose: This report illustrates the potential diagnostic and therapeutic utility of somatostatin receptor scintigraphy and therapy with somatostatin. Methods: In-111 pentetreotide (In-11 octreotide), a somatostatin analog, was used to define the receptor status and the extent of disease in a case of malignant thymoma. Results: Subsequent treatment with nonradioactive somatostatin inhibited tumor growth. Conclusion: In-111 octreotide may be useful to define tumor receptor status and may provide prognostic information useful in determining subsequent therapy.

Original languageEnglish (US)
Pages (from-to)24-28
Number of pages5
JournalClinical Nuclear Medicine
Volume24
Issue number1
DOIs
StatePublished - Jan 1999

Fingerprint

Somatostatin Receptors
Thymoma
Somatostatin
Radionuclide Imaging
Octreotide
Neoplasms
Therapeutics
Growth

Keywords

  • In-111-Octreotide Scintigraphy
  • Somatostatin Therapy
  • Thymoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma. / Lin, Ke; Nguyen, Ba D.; Ettinger, David S; Chin, Bennett B.

In: Clinical Nuclear Medicine, Vol. 24, No. 1, 01.1999, p. 24-28.

Research output: Contribution to journalArticle

@article{4a18992117e745afbaa0b59c29edfda1,
title = "Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma",
abstract = "Purpose: This report illustrates the potential diagnostic and therapeutic utility of somatostatin receptor scintigraphy and therapy with somatostatin. Methods: In-111 pentetreotide (In-11 octreotide), a somatostatin analog, was used to define the receptor status and the extent of disease in a case of malignant thymoma. Results: Subsequent treatment with nonradioactive somatostatin inhibited tumor growth. Conclusion: In-111 octreotide may be useful to define tumor receptor status and may provide prognostic information useful in determining subsequent therapy.",
keywords = "In-111-Octreotide Scintigraphy, Somatostatin Therapy, Thymoma",
author = "Ke Lin and Nguyen, {Ba D.} and Ettinger, {David S} and Chin, {Bennett B.}",
year = "1999",
month = "1",
doi = "10.1097/00003072-199901000-00006",
language = "English (US)",
volume = "24",
pages = "24--28",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma

AU - Lin, Ke

AU - Nguyen, Ba D.

AU - Ettinger, David S

AU - Chin, Bennett B.

PY - 1999/1

Y1 - 1999/1

N2 - Purpose: This report illustrates the potential diagnostic and therapeutic utility of somatostatin receptor scintigraphy and therapy with somatostatin. Methods: In-111 pentetreotide (In-11 octreotide), a somatostatin analog, was used to define the receptor status and the extent of disease in a case of malignant thymoma. Results: Subsequent treatment with nonradioactive somatostatin inhibited tumor growth. Conclusion: In-111 octreotide may be useful to define tumor receptor status and may provide prognostic information useful in determining subsequent therapy.

AB - Purpose: This report illustrates the potential diagnostic and therapeutic utility of somatostatin receptor scintigraphy and therapy with somatostatin. Methods: In-111 pentetreotide (In-11 octreotide), a somatostatin analog, was used to define the receptor status and the extent of disease in a case of malignant thymoma. Results: Subsequent treatment with nonradioactive somatostatin inhibited tumor growth. Conclusion: In-111 octreotide may be useful to define tumor receptor status and may provide prognostic information useful in determining subsequent therapy.

KW - In-111-Octreotide Scintigraphy

KW - Somatostatin Therapy

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=0032932392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032932392&partnerID=8YFLogxK

U2 - 10.1097/00003072-199901000-00006

DO - 10.1097/00003072-199901000-00006

M3 - Article

C2 - 9890489

AN - SCOPUS:0032932392

VL - 24

SP - 24

EP - 28

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 1

ER -